Accueil > Actualité
Actualite financiere : Actualite bourse

AstraZeneca: licensing agreement with RQ Biotechnology

( - AstraZeneca announces that it has entered into a licensing agreement with RQ Biotechnology for a portfolio of early stage monoclonal antibodies (mAbs) targeting SARS-CoV-2, the virus that causes Covid-19.

As part of the agreement, AstraZeneca has acquired an exclusive worldwide licence to develop, manufacture and market mAbs against SARS-CoV-2.

RQ Bio is a British biotechnology company that develops treatments and preventive therapies based on potent broad-spectrum mAbs to address unmet needs in vulnerable patient populations.

Copyright (c) 2022 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.